Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shabnam Tangri

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cytometry. Part B, Clinical Cytometry|November 15, 2011
CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphomaNaveen Dakappagari, Steffan N Ho, Randy D Gascoyne, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|September 15, 2009
An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitorsNaveen Dakappagari, Laura Neely, Shabnam Tangri, et al.
Cytometry. Part B, Clinical Cytometry|September 12, 2013
Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part III - analytical issuesShabnam Tangri, Horacio Vall, David Kaplan, et al.
Cytometry. Part B, Clinical Cytometry|June 24, 2020
Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: Benefits and challengesGhanashyam Sarikonda, Anil Pahuja, Creton Kalfoglou, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|June 11, 2002
Epitope identification and vaccine design for cancer immunotherapyAlessandro Sette, Elissa Keogh, Glenn Ishioka, et al.
Molecular Therapy. Methods & Clinical Development|February 22, 2021
Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assayLisa Davis, Nathan Riccitelli, Nancy Valencia, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2005
Rationally engineered therapeutic proteins with reduced immunogenicityShabnam Tangri, Bianca R Mothé, Julie Eisenbraun, et al.
Blood|October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Cytometry. Part B, Clinical Cytometry|December 29, 2020
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analysesGhanashyam Sarikonda, Mélissa Mathieu, Mahwish Natalia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cytometry. Part B, Clinical Cytometry|November 15, 2011
CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphomaNaveen Dakappagari, Steffan N Ho, Randy D Gascoyne, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|September 15, 2009
An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitorsNaveen Dakappagari, Laura Neely, Shabnam Tangri, et al.
Cytometry. Part B, Clinical Cytometry|September 12, 2013
Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part III - analytical issuesShabnam Tangri, Horacio Vall, David Kaplan, et al.
Cytometry. Part B, Clinical Cytometry|June 24, 2020
Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: Benefits and challengesGhanashyam Sarikonda, Anil Pahuja, Creton Kalfoglou, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|June 11, 2002
Epitope identification and vaccine design for cancer immunotherapyAlessandro Sette, Elissa Keogh, Glenn Ishioka, et al.
Molecular Therapy. Methods & Clinical Development|February 22, 2021
Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assayLisa Davis, Nathan Riccitelli, Nancy Valencia, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2005
Rationally engineered therapeutic proteins with reduced immunogenicityShabnam Tangri, Bianca R Mothé, Julie Eisenbraun, et al.
Blood|October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Cytometry. Part B, Clinical Cytometry|December 29, 2020
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analysesGhanashyam Sarikonda, Mélissa Mathieu, Mahwish Natalia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Pageof 2